Cited by 205Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.

Mechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease

Open access

Yoon, Sang-Sun, AhnJo, Sang-Mee·2012·Biomolecules and Therapeutics

DOI 10.4062/biomolther.2012.20.3.245PMC PMC3794520

Open this paper in CoChat — free account Open PDF

Abstract

Amyloid-β peptide (Aβ) is still best known as a molecule to cause Alzheimer's disease (AD) through accumulation and deposition within the frontal cortex and hippocampus in the brain. Thus, strategies on developing AD drugs have been focused on the reduc-tion of Aβ in the brain. Since accumulation of Aβ depends on the rate of its synthesis and clearance, the metabolic pathway of Aβ in the brain and the whole body should be carefully explored for AD research. Although the synthetic pathway of Aβ is equally important, we summarize primarily the clearance pathway in this paper because the former has been extensively reviewed in previous studies. The clearance of Aβ from the brain is accomplished by several mechanisms which include non-enzymatic and enzymatic pathways. Nonenzymatic pathway includes interstitial fluid drainage, uptake by microglial phagocytosis, and transport across the blood vessel walls into the circulation. Multiple Aβ-degrading enzymes (ADE) implicated in the clearance process have been identified, which include neprilysin, insulin-degrading enzyme, matrix metalloproteinase-9, glutamate carboxypeptidase II and others. A series of studies on Aβ clearance mechanism provide new insight into the pathogenesis of AD at the molecular level and suggest a new target for the development of novel therapeutics.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.4062/biomolther.2012.20.3.245

Cites

122 of 122 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1. Anabolic and catabolic pathways of amyloid-β peptide (Aβ). Aβs are synthesized from amyloid precursor protein (APP) by β-and γ-secretase and then cleared by several mechanisms includingenzyme-mediated degradation.CC BY-NC · PubMed Central

Fig. 2. Schematic presentation showing thebrain and blood vessel compartment and the ways of Aβ clearance pathways. The blood-brain barrier (BBB) is a separation of circulating blood from the brain interstitial fluid (ISF) in the central nervous system (CNS). It is composed of thin and flat endothelial cells inthe capillaries. This barrier also includes athick basement membrane, smooth musclecells and astrocytic endfeet. This barrier restricts the diffusion of most materials into the cerebral ISF. See text for details. APP: Amyloid precursor protein, ADE: Amyloid-β degradation enzyme, LRP: Low-density lipoprotein receptor-related protein, RAGE: Receptor for advanced glycation end product, CSF: Cerebrospinal fluid.CC BY-NC · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Demethylation-Linked Activation of Urokinase Plasminogen Activator Is Involved in Progression of Prostate Cancer
Pulukuri, S. M. K., Estes, N. C., Patel, J. C., & Rao, J. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2892 · Cited by 85
Retracted
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
The carboxy terminus of the .beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. Y. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,526
Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Untitled work
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Bone Marrow-Derived Microglia Play a Critical Role in Restricting Senile Plaque Formation in Alzheimer's Disease
Simard, A. R., Soulet, D., Gowing, G., Julien, J.-P., & Rivest, S. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.022 · Cited by 1,265

Show all 122 references

Research works printed but not linked: 6

1998, Am. J. Pathol., 152, 307
2006, Pharmazie, 61, 66
1996, Cell Growth Differ, 7, 787
2002, Pharmazie, 57, 556
2010, Am. J. Transl. Res., 3, 73
2006, Nat. Med., 12, 1005

Sorted by citations

Items 101–200 of 205

Change in the plasma proteome associated with canine cognitive dysfunction syndrome (CCDS) in Thailand
Phochantachinda, S., Chantong, B., Reamtong, O., & Chatchaisak, D. (2021) · BMC Veterinary Research · doi:10.1186/s12917-021-02744-w · Cited by 17
A comprehensive review on RAGE-facilitated pathological pathways connecting Alzheimer’s disease, diabetes mellitus, and cardiovascular diseases
Chakraborty, A., Sami, S. A., & Marma, K. K. S. (2021) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-021-00081-w · Cited by 18
“The equilibrium of synthesis, reuptake, and clearance of Aβ put a steady-state level in the brain but any factor that hampers this equilibrium or causes the failure of clearance effectively can cause the accumulation of Aβ, which further progress to the formation of plaques [15].”
Background
New Insights into lncRNAs in Aβ Cascade Hypothesis of Alzheimer’s Disease
Hao, Y., Xie, B., Fu, X., Xu, R., & Yang, Y. F. (2022) · Biomolecules · doi:10.3390/biom12121802 · Cited by 16
“Aβ clearance can be accomplished by a variety of mechanisms: (I) Transport of Aβ from the ISF to the CSF via lymphatic drainage [123]; (II) Endocytosis of microglia, astrocytes, and neurons leading to degradation of Aβ in lysosomes [124–127]; (III) Transport of Aβ across the blood–brain barrier (BBB) into the circulat…”
Background
Amyloid –β pathology in Alzheimer’s disease: A nano delivery approach
Meghana, G. S., Gowda, D., Chidambaram, S. B., & Osmani, R. A. M. (2023) · Vibrational Spectroscopy · doi:10.1016/j.vibspec.2023.103510 · Cited by 17
Idebenone Decreases Aβ Pathology by Modulating RAGE/Caspase-3 Signaling and the Aβ Degradation Enzyme NEP in a Mouse Model of AD
Lee, H., Jeong, H.-R., Park, J.-H., & Hoe, H. (2021) · Biology · doi:10.3390/biology10090938 · Cited by 15
Cerebral amyloid angiopathy: a narrative review
Noto, N. M., Speth, R. C., & Robison, L. S. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1632252 · Cited by 17
“In AD, A β aggregates into parenchymal plaques primarily within the frontal and parietal association cortices, with later involvement of the hippocampus (Yoon and Jo, 2012; Greenberg et al., 2020).”
The Ubiquitin E3 Ligase Nedd4 Regulates the Expression and Amyloid-β Peptide Export Activity of P-Glycoprotein
Chai, A. B., Callaghan, R., & Gelissen, I. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031019 · Cited by 15
“In healthy individuals, these peptides are efficiently cleared from the brain via cellular uptake by astrocytes, neurons and glial cells, enzymatic degradation, and export into peripheral circulation [1,2].”
Background
Secondary Prevention of Dementia: Combining Risk Factors and Scalable Screening Technology
Ojakäär, T., & Koychev, I. G. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.772836 · Cited by 12
Modulating the RAGE‐Induced Inflammatory Response: Peptoids as RAGE Antagonists
Waugh, M. L., Wolf, L. M., Turner, J. P., Phillips, L., Servoss, S. L., & Moss, M. A. (2023) · ChemBioChem · doi:10.1002/cbic.202300503 · Cited by 13
Discovery of dual cation-π inhibitors of acetylcholinesterase: design, synthesis and biological evaluation
Naresh, D., Kammari, K., Potshangbam, A. M., Rathore, R. S., Kondapi, A. K., & Vindal, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00086-2 · Cited by 13
Targeting Inflammation in Alzheimer’s Disease: Insights Into Pathophysiology and Therapeutic Avenues-A Comprehensive Review
Topalis, V., Voros, C., & Ziaka, M. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251361578 · Cited by 14
“39 Otherwise, the “ amyloidogenic ” pathways involve cleavage of APP mediated by the enzyme β -secretase 1, which results in the formation of APP β , which is further cleaved by a γ -secretase leading to the release of A β soluble fragments into the extracellular space (Figure 1) 37 .”
Tanycytic degeneration impairs tau clearance and contributes to Alzheimer’s disease pathology
Sauvé, F., Gomez-Martínez, R., Mbouamboua, Y., Ternier, G., Nampoothiri, S. S., Dupré, E., Garcia, L., Couralet, M., Dewisme, J., Lebouvier, T., et al. (2026) · Cell Press Blue · doi:10.1016/j.cpblue.2026.100003 · Cited by 15
Synthesis and Neurobehavioral Evaluation of a Potent Multitargeted Inhibitor for the Treatment of Alzheimer’s Disease
Khan, M. S., Khan, Z., Jabir, N. R., Mehan, S., Suhail, M., Zaidi, S. K., Zughaibi, T. A., Abid, M., & Tabrez, S. S. M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04351-w · Cited by 12
Dietary Strategies to Mitigate Alzheimer’s Disease: Insights into Antioxidant Vitamin Intake and Supplementation with Microbiota–Gut–Brain Axis Cross-Talk
Ngah, W. Z. W., Ahmad, H. F., Ankasha, S. J., Makpol, S., & Tooyama, I. (2024) · Antioxidants · doi:10.3390/antiox13121504 · Cited by 12
Exosomes and non-coding RNAs: bridging the gap in Alzheimer’s pathogenesis and therapeutics
Chunhui, G., You, Y., Chen, J., Luo, N., & Li, F. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-024-01520-7 · Cited by 13
“…to the clearance of Aβ (Liu et al. 2017; Mandrekar et al. 2009 ); (III) Aβ can enter the circulation by crossing the blood-brain barrier (Storck et al. 2018 ; Van Gool et al. 2019 ); and (IV) the degradation of Aβ can also occur through the action of extracellular proteases (Yoon and Jo 2012 ).”
Stimulating the Activity of Amyloid-Beta Degrading Enzymes: A Novel Approach for the Therapeutic Manipulation of Amyloid-Beta Levels
Kuruppu, S., Rajapakse, N. W., Spicer, A. J., Parkington, H. C., & Smith, A. I. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160492 · Cited by 12
Age-Dependent Changes in the Plasma and Brain Pharmacokinetics of Amyloid-β Peptides and Insulin
Zhou, A. L., Sharda, N., Sarma, V., Ahlschwede, K. M., Curran, G. L., Tang, X., Poduslo, J. F., Kalari, K. R., Lowe, V. J., & Kandimalla, K. K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215128 · Cited by 12
Potent therapeutic targets for treatment of Alzheimer's disease: Amyloid degrading enzymes
Choi, H. S., Kim, E., Choi, J. Y., Park, E., & Lee, H. J. (2021) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12390 · Cited by 11
Sorghum Grain Polyphenolic Extracts Demonstrate Neuroprotective Effects Related to Alzheimer’s Disease in Cellular Assays
Rezaee, N., Hone, E., Sohrabi, H. R., Johnson, S. K., Zhong, L., Chatur, P., Gunzburg, S. T., Martins, R. N., & Fernando, W. M. A. D. B. (2024) · Foods · doi:10.3390/foods13111716 · Cited by 11
“In addition, the HPLC analysis revealed that QL33 had high levels of caffeic acid, ferulic acid, and apigenin, which were previously shown to be highly effective in attenuating A β toxicity [41,45,46].”
Background
Effect of Lycoris chejuensis and Its Active Components on Experimental Models of Alzheimer’s Disease
Kim, J., Park, Y., Chun, Y. S., Cha, J. W., Kwon, H. C., Oh, M. S., Chung, S., & Yang, H. O. (2015) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5b00889 · Cited by 11
Precious but convenient means of prevention and treatment: physiological molecular mechanisms of interaction between exercise and motor factors and Alzheimer’s disease
Hao, Z., Liu, K., Zhou, L., & Chen, P. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1193031 · Cited by 10
β-Amyloids and Immune Responses Associated with Alzheimer’s Disease
Kolobova, E. A., Petrushanko, I. Y., Mitkevich, V. A., Makarov, A. А., & Grigorova, I. (2024) · Cells · doi:10.3390/cells13191624 · Cited by 10
“Any change in the dynamic equilibrium maintained by the production, removal, and transportation of A β can lead to its accumulation and aggregation [69,70] (Figure 1).”
Background
Plasma Cytokines Profile in Subjects with Alzheimer’s Disease: Interleukin 1 Alpha as a Candidate for Target Therapy
Mahdavi, M., Karima, S., Rajaei, S., Aghamolaii, V., Ghahremani, H., Ataeia, R., Tehrani, H. S., Baram, S. M., Tafakhori, A., Lima, B. S., et al. (2021) · Galen Medical Journal · doi:10.31661/gmj.v10i0.1974 · Cited by 10
Research on the Glial–Lymphatic System and Its Relationship With Alzheimer’s Disease
Ding, D., Wang, X., Li, Q., Li, L., & Wu, J. W. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.605586 · Cited by 11
Anodal transcranial direct current stimulation alleviates cognitive impairment in an APP/PS1 model of Alzheimer’s disease in the preclinical stage
Luo, Y.-P., Liu, Z., Wang, C., Wang, C., Wu, X., Tian, X., & Wen, H. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.337053 · Cited by 10
“…of APP/PS1 mice APP, β-site amyloid precursor protein cleaving enzyme 1 (BACE1), a disintegrin and metalloprotease domain 10 (ADAM10), neprilysin (NEP, also known as CD10), and insulin-degrading enzyme (IDE) are associated with Aβ metabolism (Yoon and Jo, 2012; Barage and Sonawane, 2015).”
Transcranial Magneto-Acoustic Stimulation Protects Synaptic Rehabilitation from Amyloid-Beta Plaques via Regulation of Microglial Functions
Zhang, C., Tan, R., Zhou, X., Wang, R., Wang, X., Ma, R., Chu, F., Li, Y., Yin, T., & Liu, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094651 · Cited by 9
“Currently, strategies to enhance the clearance of A β still hold promise for AD treatment and prevention [4].”
Background
Pharmacological inhibition of receptor protein tyrosine phosphatase β/ζ decreases Aβ plaques and neuroinflammation in the hippocampus of APP/PS1 mice
Fontán‐Baselga, T., Cañeque‐Rufo, H., Rivera-Illades, E., Gramage, E., Zapico, J. M., de Pascual‐Teresa, B., Ramos, P., Herradón, G., & Vicente‐Rodríguez, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1506049 · Cited by 9
Emerging Role of Mesenchymal Stromal Cell and Exosome Therapies in Treating Cognitive Impairment
Tew, V. K., Barathan, M., Nordin, F., Law, J. X., & Ng, M. H. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030284 · Cited by 9
“This inhibition is accompanied by a promotion of A β clearance, alteration in amyloid precursor protein (APP) processing, and a decrease in tau phosphorylation [108].”
Intervention points for the role of physical activity in prevention and treatment of Alzheimer's disease
Brendborg, N., & Febbraio, M. A. (2025) · The Journal of Physiology · doi:10.1113/jp286747 · Cited by 10
MitoTempo protects against nε-carboxymethyl lysine-induced mitochondrial dyshomeostasis and neuronal cells injury
Carvalho, C., & Moreira, P. I. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.05.011 · Cited by 10
Plasma amyloid beta level changes in aged mice with cognitive dysfunction following sevoflurane exposure
Liang, R., Ou, S., Han, Y., Xu, J., & Zhou, S. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110737 · Cited by 9
The role of amyloid β in the pathological mechanism of GNE myopathy
Zhang, T., Shang, R., & Miao, J. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06301-7 · Cited by 10
Synergistic Role of Aerobic Training and Resveratrol on AMPK/PGC1-α/SIRT1 Pathway in the Hippocampus of Rats with Alzheimer's Disease
Rashet, A., Abdi, A., & Barari, A. (2024) · Journal of Archives in Military Medicine · doi:10.5812/jamm-144281 · Cited by 9
Anticholinergic Drugs Interact With Neuroprotective Chaperone L-PGDS and Modulate Cytotoxicity of Aβ Amyloids
Low, K. J. Y., Phillips, M., & Pervushin, K. V. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00862 · Cited by 8
Thyroid Hormone and Alzheimer Disease: Bridging Epidemiology to Mechanism
Escamilla, S., & Salas-Lucia, F. (2024) · Endocrinology · doi:10.1210/endocr/bqae124 · Cited by 9
How Can We Use Mathematical Modeling of Amyloid-β in Alzheimer’s Disease Research and Clinical Practices?
Chu, C., Low, Y. L., Ma, L., Wang, Y., Cox, T. O., Doré, V., Masters, C. L., Goudey, B., Jin, L., & Pan, Y. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230938 · Cited by 7
Acute Hyperglycemia Induced by Hyperglycemic Clamp Affects Plasma Amyloid-β in Type 2 Diabetes
Rolandsson, O., Tornevi, A., Steneberg, P., Edlund, H., Olsson, T., Andréasson, U., Zetterberg, H., & Blennow, K. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230628 · Cited by 7
“There are many mechanisms for A (cid:2) clearance in the CNS, including both enzymatic, such as IDE, and non-enzymatic pathways [17].”
Misfolded proteins as a therapeutic target in Alzheimer's disease
Liyanage, S. I., & Weaver, D. F. (2019) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.08.003 · Cited by 8
Ms4a4a deficiency ameliorates plaque pathology in a mouse model of amyloid accumulation
Danhash, E., Verbeck, A. C., Western, D., Díaz‐Pacheco, A. S., Galasso, G., You, S., Huang, G., Starr, E., Miller, N., Nadarajah, C. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70580 · Cited by 6
“54 A number of proteolytic enzymes have been shown to degrade A β , including IDE, 55–57 NEP, 58,59 MMP-9, 60–62 and cathepsin B. 63,64 IDE is enriched in astrocytes and only degrades monomeric A β , while NEP is expressed in neurons where it degrades A β monomers and small oligomers.”
Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease
Mir, R. H., Masoodi, M. H., Shah, A. J., Mohi-ud-din, R., Sabreen, S., Wani, T. U., Jan, R., Javed, M. N., & Mir, P. A. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220903095837 · Cited by 6
iTRAQ-Based Proteomic Analysis of APP Transgenic Mouse Urine Exosomes
Zhou, X., Sheikh, A. M., Matsumoto, K., Mitaki, S., Shibly, A. Z., Zhang, Y., Garu, A., Yano, S., & Nagai, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010672 · Cited by 6
“After production, the peptide is removed from the brain by enzymatic degradations and cell- and vessel-mediated clearance [15].”
Background
Plaque attack: Microglia have hard feelings toward amyloid-β
Davis, H., & Attwell, D. (2023) · Neuron · doi:10.1016/j.neuron.2022.11.014 · Cited by 7
In-vitro studies of curcumin encapsulated mesoporous Fe-Phenanthroline nanocluster for reduction of amyloid β plaque
Sharma, A., Yadav, A., Cwiklinski, K., Quaye, E., Aalinkeel, R., Mahajan, S. D., Schwartz, S. A., & Sharma, R. K. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101314 · Cited by 6
Tanycytes are degraded in Alzheimer’s Disease, disrupting the brain-to-blood efflux of TauPreprint
Sauvé, F., Ternier, G., Dewisme, J., Lebouvier, T., Dupré, E., Danis, C., Rasika, S., Kim, Y., Ciofi, P., Giacobini, P., et al. (2022) · medRxiv · doi:10.1101/2022.05.04.22274181 · Cited by 7
Targeting Amyloid-β Proteins as Potential Alzheimer’s Disease Therapeutics: Anti-Amyloid Drug Discovery, Emerging Therapeutics, Clinical Trials and Implications for Public Health
Abduljawad, A. A., Alkinani, K. B., Zaakan, A., AlGhamdi, A. S., Hamdoon, A. A. E., Alshanbari, B. H., Alshehri, A. A., Alluhaybi, B. B., Alqashi, S. O. I., & Abduljawad, R. A. (2025) · Pharmaceuticals · doi:10.3390/ph18111731 · Cited by 7
“Being a highly complex and multifactorial neurodegenerative disease, an understanding of the molecular mechanisms of AD is extremely important for the development of safe and effective therapeutic agents [41].”
Aβ dissociation by pectolinarin may counteract against Aβ-induced synaptic dysfunction and memory impairment
Yi, J. H., Cho, E., Lee, S., Kwon, K. J., Lee, S., Lee, J., Lee, C., Shin, C. Y., Kim, D. H., & Shim, S. H. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115792 · Cited by 5
The growth rate of senile plaques is determined by the competition between the rate of deposition of free Aβ aggregates into plaques and the autocatalytic production of free Aβ aggregates
Kuznetsov, A. V. (2024) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2024.111900 · Cited by 5
CD38-NAD(+) Axis: New Insights into Glaucoma Therapy
Zhang, W., Zheng, H., Pang, Y., Wang, Y., & Zhang, X. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05243-3 · Cited by 6
“These cells also exhibit the capability to phagocytose amyloid-beta (Aβ) aggregates linked to Alzheimer’s disease pathology [77].”
Late-onset alzheimer’s disease, atherosclerosis, and cerebrovascular disease. A complex relationship too often neglected: a narrative review
Zuliani, G., & Cervellati, C. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03217-y · Cited by 4
Aluminum chloride in Alzheimer's disease: A dual focus on molecular mechanisms and rat experimental models
Khattab, N. A., El-Kadem, A. H., Goda, A. E., El‐Mahdy, N. A., & El‐Shitany, N. A. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115814 · Cited by 4
Evaluation of Aβ Deposits in the Hippocampus of a Rat Model of Alzheimer’s Disease After Intravenous Injection of Human Adipose Derived Stem Cells by Immuno- and Thioflavin S-Costaining
Doshmanziari, M., Sarveazad, A., Moradi, F., Shariatpanahi, M., Doshmanziari, E., Simorgh, S., & Eftekharzadeh, M. (2019) · Thrita · doi:10.5812/thrita.88367 · Cited by 4
Linking Cognitive Impairment with Amyloid-β Accumulation in Alzheimer’s Disease: Insights from Behavioral Tests and FTIR Spectroscopy
Gaber, H. A., Aly, E. M., Mohamed, E. S., Elfoly, M., Rabie, M. A., Talaat, M. S., & El-Sayed, E.-S. M. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230051 · Cited by 5
Hormone replacement therapy and Alzheimers disease in older women: A systematic review of literature
Abdu, W. I., Olufunke, A. S., Ibrahim, A. M., & Machina, B. K. (2018) · Journal of Neuroscience and Behavioral Health · doi:10.5897/jnbh2017.0148 · Cited by 5
“enzymes (Jaffe et al., 1994; Xiao et al., 2009; Liang et al., 2010; Yoon and Jo, 2012) (5) Increasing cerebral glucose transportation and”
Background
Blood-based therapies to combat neurodegenerative diseases
Jy, L., Lim, M. C. X., Koh, R. Y., Tsen, M. T., & Chye, S. M. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01368-x · Cited by 3
“Previous studies have demonstrated that brain-derived Aβ is found in the systemic circulation at different sites (Man - ess et al. 1994 ; Roberts et al. 2014) due to the multiple brain-to-blood efflux transport mechanisms (Yoon and Jo 2012).”
Role of non-neuronal cells in neurorepair: a focus on proteinopathy and neurodegeneration
Rodríguez-Carreiro, S., Nogales, M. D. C., Jiménez-Galán, D., Carmona-Lorenzo, S., Caro-Martín, A., Navarro, E., & Esteras, N. (2024) · Regenerative medicine reports . · doi:10.4103/regenmed.regenmed-d-24-00005 · Cited by 2
Halting the Progression of Alzheimer’s Disease: Is the Goal in Sight?
Jia, Y., Wang, X.-Y., Liu, J., Wang, Y., Masters, C. L., & Guo, J. (2024) · Neuroscience Bulletin · doi:10.1007/s12264-024-01339-3 · Cited by 3
“Under physiological conditions, excess Aβ is primarily cleared from the brain through microglial phagocytosis and the glymphatic system, which involves cerebrospinal fluid and blood circulation [7].”
Role of Copper and Zinc Ions in the Hydrolytic Degradation of Neurodegeneration-Related Peptides
Pirota, V., Monzani, E., Dell’Acqua, S., & Bacchella, C. (2025) · Molecules · doi:10.3390/molecules30020363 · Cited by 3
Justicidin A Reduces β-Amyloid via Inhibiting Endocytosis of β-Amyloid Precursor Protein
Chun, Y. S., Kwon, O.-H., Oh, H. G., Cho, Y. Y., Yang, H. O., & Chung, S. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.112 · Cited by 3
Benzimidazole Derivatives in Alzheimer’s Therapy: Exploring Multi-Target Pathways
Gavade, S., Dubey, S., & Tiwari, P. K. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037387954250901202157 · Cited by 4
Decoding the secretase puzzle in amyloid-β generation: A state-of-the-art overview of the protease-mediated APP processing cascade in Alzheimer’s disease
Senkowska, Z., & Węglarz‐Tomczak, E. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103116 · Cited by 2
Repercussions of microglial efferocytosis on neurodegeneration in Alzheimer’s Disease (AD): a double-edged sword and perplexing factor warranting scrutiny in AD research
Kanuri, S. H. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-024-00853-5 · Cited by 2
“Extra-cellular mechanisms that were hypothesized for purging these pathological aggregates include proteases and microglial phagocytosis [30, 31].”
Background
A Comprehensive and Concise Review on Significance of Potent Peptide; Amyloid Beta (Aβ) in Progression of Alzheimer’s Disease
Aziz, N., Wal, P., Singh, Y. K., Kumar, P., & Singh, B. (2024) · Current Drug Therapy · doi:10.2174/0115748855299317241014051505 · Cited by 2
Can the inhibition of glycogen synthase kinase 3 mimic the physiological effects of exercise on muscle and other organs?
Hockey, B. L., Braun, J. L., Vandenboom, R., LeBlanc, P. J., MacPherson, R. E. K., & Fajardo, V. A. (2025) · Advanced Exercise and Health Science · doi:10.1016/j.aehs.2025.06.001 · Cited by 2
Kaempferide and Norbergenin avert aluminium chloride-induced amyloid β accumulation and neurocognitive shutdown via oxidative and apoptotic mechanisms
Nalla, S., Ganta, S., Bukke, S. P. N., Bandaru, N., Onohuean, H., & Alagbonsi, A. I. (2025) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320251343687 · Cited by 2
“56 Therefore, the imbalance between the production-clearance processes can lead to its accumulation in the brain.”
Gene expression changes implicate specific peripheral immune responses to Deep and Lobar Intracerebral Hemorrhages in humans
Knepp, B., Ander, B. P., Jickling, G. C., Hull, H., Yee, A., Ng, K., Rodríguez, F., Carmona-Mora, P., Amini, H., Zhan, X., et al. (2022) · Brain Hemorrhages · doi:10.1016/j.hest.2022.04.003 · Cited by 2
“155 Neither associated with Deep ICH.”
Investigation of the potential connections between NAFLD-associated Alzheimer's disease: bioinformatics analysis of shared genesPreprint
Bhattacharya, I., Bhattacharya, T., Sahu, A., Das, P., Sarkar, S., Prasanna, V. S., Sreed, R., Ravichandiran, V., & Arumugam, S. (2024) · Research Square · doi:10.21203/rs.3.rs-4667019/v1 · Cited by 2
Cerebrospinal Fluid Biomarkers of Alzheimer Disease
Васильевна, Н. К., Shpilyukova, Y. A., Шабалина, А. А., Fedotova, E. Y., & Illarioshkin, S. N. (2025) · Annals of Clinical and Experimental Neurology · doi:10.17816/acen.1185 · Cited by 1
Intersection of COVID-19 and Alzheimer’s Disease: Genetic Insights and Neuropathological Consequences
Balakrishnan, R., Subbarayan, R., Shrestha, R., & Chauhan, A. (2025) · Biochemical Genetics · doi:10.1007/s10528-025-11208-x · Cited by 1
Pathological and Functional Brain Amyloids: A New Concept Explaining the Differences
Galkin, A. P., Mitkevich, V. A., Makarov, A. А., Valina, A. A., & Sysoev, E. I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110459 · Cited by 1
“A β clearance occurs through both enzymatic and non-enzymatic pathways [96].”
Cross-seeding of IAPP and Aβ42: A review of the molecular link between type 2 diabetes and Alzheimer’s disease
Babu, P. R., Turner, C., & Ryznar, R. J. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01767-8 · Cited by 1
“Mononuclear phagocytes in the brain, known as microglia, have the ability to clear Aꞵ through degradation of soluble and fibrillar forms (Yoon and Jo 2012 ).”
Bidirectional relationship between the biofilm of Porphyromonas gingivalis and the amyloid-beta peptide
Dumoulin, D., Ghrayeb, M., Côté, S., Garneau, D., Chai, L., Frost, E. H., Fülöp, T., & Beauregard, P. B. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.01981-25 · Cited by 2
Targeted Protein Degrader from Ginkgo to Mitigate Amyloid β-Induced Neurotoxicity
Dutta, B., Loo, S., Kam, A., Liu, C., & Tam, J. P. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00763 · Cited by 1
Vitamin D3 Attenuates Alzheimer’s Disease-Like Pathology via Remodeling Amyloid Protein Production and Clearance Pathway in Wistar Rats
Tripathi, P., & Shah, J. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04721-x · Cited by 1
Association between Cerebral Small Vessel and Alzheimer’s Disease
Lee, K. H., & Kang, K. M. (2022) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2022.0041 · Cited by 1
“는 것으로 알려져 있는데(25), 이를 통한 과정이 원활하지 않을 때 알츠하이머병 진행이 촉진된다 고 알려져 있다(26).”
Aging and brain free cholesterol concentration on amyloid‐β peptide accumulation in guinea pigs
Pang, K. S., Peng, H., Li, B. P., Wen, B., Noh, K., Xia, R., Toscan, A., Serson, S., Fraser, P. E., Tirona, R. G., et al. (2024) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2386 · Cited by 1
“…‐ onset) form of Alzheimer’s disease due to reduced A β peptide catabolism by neprilysin (Briones & Darw-ish, 2013; Hardy & Selkoe, 2002; Iwata et al., 2005; Yoon & Jo, 2012), and efflux by P ‐ gp and LRP1 (Briones & Darwish, 2013; Iwata et al., 2005; Shibata et al., 2000; Toornvliet et al., 2006).”
Background
Traumatic Brain Injury and Alzheimer’s Disease: Exploring the Pathological Overlap and Risk of Neurodegeneration
Mavroudis, I. A., Petridis, F., Kazis, D. A., Ionescu, C., Novac, B., Petroaie, A. D., Novac, O., Gurzu, I. L., & Gurzu, B. (2025) · BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE · doi:10.70594/brain/16.2/1 · Cited by 1
Contribution of Neuroinflammation in the Pathogenesis of Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00006-9 · Cited by 1
Alveolar early progenitors in the aged human lung have increased expression of ACE2 accompanied with genes involved in beta-amyloid clearance: Indication of SARS-CoV-2 also using soluble ACE2 in aged-lungs to enter ACE2-negative cellsPreprint
Chaudhri, V. K. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.25.115774 · Cited by 1
“Beta-amyloid clearance is a well-studied process in relation to Alzheimer’s in the human brain, where several are proteases and peptidase are secreted, in response to extracellular beta-amyloid accumulation (Panza et al., 2019; Yoon and Jo, 2012).”
Background
Anti-Obesity, Cognitive Enhancing, Neurobehavioral, Antioxidant Effects And Phytochemical Profile Of Dichloromethane Leaf Extract Of Gnidia Glauca (Fresen)
Makori, W. A. (2019)
Alzheimer’s disease as a syndrome of overloaded amyloidic synaptic tagging in memory networksPreprint
Murphy, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/7gsaz
Research Progress of Stem Cell Exosomes in Alzheimer’s Disease
古, 良. (2023) · Bioprocess · doi:10.12677/bp.2023.132013
Linking the Meso and Macroscale Determinants of Cerebral AgeingPreprint
Paolo, R. D., Deery, H. A., & Jamadar, S. D. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/8n4ud
A Systematic Review on Nano Drug Delivery Approaches to Ameliorate Therapeutic Values in Alzheimer’s Disease
Singh, S., Sharma, N., Singh, V. P., & Sharma, A. (2025) · Current Nanomedicine · doi:10.2174/0124681873330947241230054603
Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Tyagi, N., Pal, S., & Bisht, D. (2025) · Springer eBooks · doi:10.1007/978-981-96-6202-9_13 · Cited by 1
Infusion of blood from young and old mice modulates amyloid pathology
Pizarro, M., Gomez‐Gutierrez, R., Caviedes, A., Valdes, C., Woehlbier, U., Vargas, C., Hernández, M., Duran-Aniotz, C. A., & Morales, R. (2025) · Aging · doi:10.18632/aging.206319
“These findings underscore the diverse approaches that leverage blood-based mechanisms for Aβ clearance, providing valuable insights for the development of effective therapeutic interventions [25, 26].”
Effects of Dietary Vitamin D Levels on Markers Related to Amyloidogenesis and Neuroinflammation in db/db Mice
Kim, J., Wi, D., Han, S. N., & Park, C. Y. (2025) · Nutrients · doi:10.3390/nu17213339 · Cited by 1
Cortical Bone Loss and Fragility in a 2-Month Triple Transgenic Mouse Model of Alzheimer’s Disease
Storlino, G., Posa, F., Dell'Endice, T. S., Piccolo, F., Colaianni, G., Cassano, T., Grano, M., & Mori, G. (2025) · Cells · doi:10.3390/cells14221816
“Furthermore, it has been proven that the presence of A β plaques can increase bone resorption through the activation of osteoclastogenesis marker genes (Cathepsin K and TRAP) led by RANKL [25,26].”
Decabromodiphenyl ethane as a neurotoxicant in Alzheimer’s disease: unraveling its mechanisms through the integration of multiple computational toxicology methods
Li, J., Liu, J., Zhou, M., Xu, J., Xiao, Y., Fan, X., & Xu, W. (2025) · Drug and Chemical Toxicology · doi:10.1080/01480545.2025.2592931
“Furthermore, PlaU dysfunction contributes to impaired amyloid-β (aβ) clearance mechanisms (Gaweda-Walerych et al., 2021; Yoon & Jo, 2012), with elevated PlaU expression correlating directly with compromised aβ clearance efficiency and enhanced aβ plaque deposition.”
Mitigation of Aβ 25-35 -Induced Cognitive Deficits in C57BL/6 Mice via Thermal Cycling Stimulation Employing Focused UltrasoundPreprint
Lin, G.-B., Liu, H.-H., Kuo, Y.-Y., Chen, Y.-M., Hsu, F.-T., Wang, Y.-W., Kung, Y., Ching, C., & Chao, C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.10.693347
Additional file 2 of Change in the plasma proteome associated with canine cognitive dysfunction syndrome (CCDS) in Thailand
Phochantachinda, S., Chantong, B., Reamtong, O., & Chatchaisak, D. (2021) · Figshare · doi:10.6084/m9.figshare.13668053
Additional file 1 of Change in the plasma proteome associated with canine cognitive dysfunction syndrome (CCDS) in Thailand
Phochantachinda, S., Chantong, B., Reamtong, O., & Chatchaisak, D. (2021) · Figshare · doi:10.6084/m9.figshare.13668050
Additional file 4 of Change in the plasma proteome associated with canine cognitive dysfunction syndrome (CCDS) in Thailand
Phochantachinda, S., Chantong, B., Reamtong, O., & Chatchaisak, D. (2021) · Figshare · doi:10.6084/m9.figshare.13668059
Investigating gender differences in Alzheimer's disease
Fouad, G. I., Ando, H., & Ichihara, G. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877251410204 · Cited by 2
“In the brain, A β is hydrolyzed through the proteolytic machinery, 131 and more than 20 different A β -degrading enzymes (ADEs) have been identi ﬁ ed 132 ; metalloproteases are ADEs, with matrix metalloprotease 2 (MMP-2), MMP-7, and MMP-9 showing A β -degrading activity and association with AD.”
Génération de cellules souches pluripotentes induites de patients Alzheimer et production d'un modèle de culture en trois dimensions de neurones pour les recherches diagnostiques et thérapeutiques de la maladie d’Alzheimer
Auboyer, L. (2018) · theses.fr (ABES) · doi:10.70675/07243ef7zb974z4ad8z97d9zd046801798b1
Implications de la protéine DYRK1A dans la pathologie Alzheimer et développement de stratégies thérapeutiques
Souchet, B. (2018) · theses.fr (ABES) · doi:10.70675/5510ef76zecf1z41f2z9496z015aa6a093be
Impact des pesticides sur l'agrégation des amyloïdes dans différents modèles de maladies neurodégénératives
Lafon, P. (2019) · theses.fr (ABES) · doi:10.70675/a7f03da1zde57z4475zb05bzc90240451d1c
Early memory deficits and extensive brain network disorganization in the AppNL-F/MAPT double knock-in mouse model of familial Alzheimer's disease
Borcuk, C. (2021) · theses.fr (ABES) · doi:10.70675/c316f2dcz54d3z41cfzb3f5z99c7b2d3cd95 · Cited by 1
Myelin alterations in early stages of Alzheimer's disease and preclinical assessment of the protective and therapeutic potential of neurosteroid 3α-O-allyl-allopregnanolone
Okechukwu, N. G. (2023) · theses.fr (ABES) · doi:10.70675/ec1ca2c3zfad7z48b7zba08z6bb3bb44334f
Lactic Acid Bacteria-Mediated Fermentation Drives Metabolic Remodeling of Centella Asiatica (L.) Urb. toward Acidic Triterpenoids with Neuroinflammation-Related Bioactivity
Ryu, D. H., Cho, J. Y., Jung, J. W., Ho, H.-T., Kim, H. M., Park, N.-Y., Ahn, N.-H., Lee, J.-H., Park, J.-S., Lee, D.-S., et al. (2026) · ACS Omega · doi:10.1021/acsomega.6c00935
Tetrapeptide inhibitors of BACE-1 revealed by combined data-driven screening and physics-based free-energy refinement
Nguyen, T. H., Nguyen, H. N. T., Pham, M. Q., & Phùng, H. T. T. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11653-9

Authors: Yoon, S.-S., & AhnJo, S.-M.
Affiliations: Dankook University (KR)
ORCID: Yoon, Sang-Sun
Venue: Biomolecules and Therapeutics
Publisher: The Korean Society of Applied Pharmacology
Published: 2012-05-31
Volume: 20
Issue: 3
Pages: 245-255
ISSN: 1976-9148 (ISSN-L)
DOI: 10.4062/biomolther.2012.20.3.245
PMC: PMC3794520
OpenAlex: W2008487250
Cited by: 205
References: 122
Citations by year: 2026: 15 · 2025: 27 · 2024: 27 · 2023: 23 · 2022: 14 · 2021: 26 · 2020: 18 · 2019: 15 · 2018: 11 · 2017: 9 · 2016: 6 · 2015: 9 · 2014: 1 · 2013: 3 · 2012: 1
FWCI: 0.49
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Biomolecules & Therapeutics (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion, cc-by-nc)
PubMed (publishedVersion)
Funders: National Research Foundation
National Research Foundation of Korea (2011-0016127)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: amyloid-beta, Alzheimer's disease, amyloid-beta clearance, neprilysin, insulin-degrading enzyme, MMP-9, prostate-specific membrane antigen, microglial phagocytosis, interstitial fluid drainage, blood-brain barrier, therapeutic target

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks